|Bid||452.00 x 0|
|Ask||453.50 x 0|
|Day's Range||448.50 - 485.50|
|52 Week Range||414.00 - 1,678.00|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||1,956.52|
|Earnings Date||Sep 20, 2022 - Sep 26, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,349.50|
Subscribe to Yahoo Finance Plus to view Fair Value for OXB.L
Oxford Biomedica plc (OTC: OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the original commitment, is expected to complete in the last quarter of 2022. Under the expanded deal, AstraZen
Oxford BioMedica has extended its partnership with AstraZeneca, agreeing a new three-year contract to manufacture Covid-19 vaccines if the UK drugmaker presses on with mass production of the jab. The specialist pharmaceutical manufacturer, which also makes cell and gene therapies, will make its Oxbox facility available on an “as needed” basis to AstraZeneca after 2022. The original contract signed in September 2020 is expected to complete in the last quarter of this year, with Oxford BioMedica recognising roughly £30mn from AstraZeneca this financial year.
Oxford Biomedica (LON:OXB) has had a rough three months with its share price down 35%. However, stock prices are...